You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Article metrics

Article menu

This article has a correction. Please see:

XML
Clinical/translational cancer immunotherapy
Original research
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

 

Online download statistics by month:

Online download statistics by month: July 2020 to February 2026

AbstractFullPdf
Jul 202011821182734
Aug 2020557552334
Sep 2020514514343
Oct 2020470470387
Nov 2020500498225
Dec 2020378378173
Jan 2021359359192
Feb 2021424424192
Mar 2021598598233
Apr 2021510510185
May 2021462462225
Jun 2021518518189
Jul 2021410410162
Aug 2021315315135
Sep 2021460460203
Oct 2021433433212
Nov 2021568571216
Dec 2021311313120
Jan 2022322330152
Feb 2022387401124
Mar 2022449453158
Apr 2022641666203
May 2022398430187
Jun 2022405418161
Jul 2022444446115
Aug 2022482491137
Sep 2022460467136
Oct 2022463475151
Nov 2022471471141
Dec 2022443443113
Jan 202339439689
Feb 2023387387114
Mar 202311271131116
Apr 2023333335129
May 202331531790
Jun 202329229384
Jul 202329730087
Aug 202327928296
Sep 202319219486
Oct 202324624793
Nov 2023367367110
Dec 202339839994
Jan 202415015173
Feb 2024206206110
Mar 2024303304157
Apr 2024286290145
May 202421121187
Jun 2024201202114
Jul 202418918966
Aug 2024193187100
Sep 202416916985
Oct 202417918472
Nov 202420320489
Dec 202424324670
Jan 202516917074
Feb 202516816760
Mar 202517618064
Apr 202520320364
May 202514614867
Jun 202510510542
Jul 2025110
Aug 2025110
Feb 2026110
Total22464226258965